FDC Limited announced its unaudited financial results for the second quarter and half-year ended September 30, 2026. The company reported a 21.0% year-on-year increase in revenue from operations for Q2 FY27, reaching Rs. 572 crores. Profit after tax (PAT) saw a substantial 72.9% jump to Rs. 49 crores. For the half-year ended H1 FY27, revenue grew by 10.6% to Rs. 1,240 crores, with PAT rising by 21.3% to Rs. 181 crores.
FDC Limited Reports Strong Q2 and H1 FY27 Financials
FDC Limited has announced robust financial results for the second quarter (Q2) and the first half (H1) of the financial year 2026-27, ending September 30, 2026. The company achieved a significant 21.0% year-on-year growth in revenue from operations for Q2 FY27, amounting to Rs. 572 crores, up from Rs. 473 crores in Q2 FY26. This growth was attributed to a recovery in Domestic Formulations and sustained performance in International Formulations.
Key Financial Highlights
Profit After Tax (PAT) for Q2 FY27 surged by an impressive 72.9% to Rs. 49 crores, compared to Rs. 28 crores in the corresponding quarter of the previous year. Earnings Per Share (EPS) also saw a substantial increase, rising to Rs. 3.01 from Rs. 1.75.
Half-Year Performance (H1 FY27)
For the six months ended September 30, 2026 (H1 FY27), FDC Limited reported consolidated revenue from operations of Rs. 1,240 crores, marking a 10.6% increase over Rs. 1,121 crores in H1 FY26. Profit After Tax for H1 FY27 grew by 21.3% to Rs. 181 crores, compared to Rs. 150 crores in the prior year. The EPS for H1 FY27 stood at Rs. 11.15.
Segment Performance
In Q2 FY27, Domestic Formulations revenue reached Rs. 467 crores, a 22.6% increase driven by flagship brands like Electral and Enerzal. International Formulations contributed Rs. 75 crores in Q2 FY27, showing a 28.5% growth. The API business recorded sales of Rs. 28 crores for the quarter.
For H1 FY27, Domestic Formulations revenue was Rs. 1,036 crores (up 7.8%), and International Formulations sales were Rs. 148 crores (up 47.6%). The API segment recorded sales of Rs. 52 crores for H1 FY27.
Market Position
FDC Limited was also recognized as the fastest-growing company among the top 25 corporates in the Indian Pharmaceutical Market in Q2 FY27, according to IQVIA data.
Source: BSE
